---
title: UK pharma media reputation tracker – July 2026
canonical_url: https://www.omniscan.ai/benchmarks/uk-pharma-2026-07
type: dataset
publisher: Omniscan
sector: Pharma in the UK
period: July 2026
coverage_start: '2026-07-01'
coverage_end: '2026-07-31'
date_published: '2026-09-01'
last_updated: '2026-09-01'
organisations: 10
articles_analysed: 978
mentions: 831
data_download: https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/data.json
summary: AstraZeneca had the highest average monthly share of coverage (29.2%) among
  10 companies in UK earned media from 1 July 2026 to 31 July 2026, ahead of GSK (23.7%)
  and Novo Nordisk (16.8%).
---

# UK pharma media reputation tracker: July 2026 (1 July 2026–31 July 2026)

> AstraZeneca had the highest average monthly share of coverage (29.2%) among 10 companies in UK earned media from 1 July 2026 to 31 July 2026, ahead of GSK (23.7%) and Novo Nordisk (16.8%). Roche had the most favourable net tone (+73). Omniscan analysed 978 articles containing 831 mentions of the companies tracked.

Interactive version: https://www.omniscan.ai/benchmarks/uk-pharma-2026-07

## Pharma in the UK ranking by share of coverage, July 2026

| Rank | Organisation | Average monthly share of coverage | Mentions | Positive | Neutral | Negative | Net tone |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | AstraZeneca | 29.2% | 243 | 41% | 32% | 27% | +14 |
| 2 | GSK | 23.7% | 197 | 46% | 39% | 15% | +30 |
| 3 | Novo Nordisk | 16.8% | 140 | 28% | 56% | 16% | +13 |
| 4 | Eli Lilly | 11.7% | 97 | 23% | 59% | 18% | +4 |
| 5 | Novartis | 5.8% | 48 | 77% | 17% | 6% | +71 |
| 6 | Pfizer | 4.3% | 36 | 36% | 36% | 28% | +8 |
| 7 | Roche | 2.6% | 22 | 73% | 27% | 0% | +73 |
| 8 | MSD | 2.4% | 20 | 25% | 45% | 30% | −5 |
| 9 | Moderna | 2.0% | 17 | 29% | 65% | 6% | +24 |
| 10 | Sanofi | 1.3% | 11 | 27% | 46% | 27% | 0 |

## Companies in detail

### AstraZeneca

**Financial Results & Pipeline shaped AstraZeneca's media profile during July 2026**

AstraZeneca ranked 1st of 10 by average monthly share of coverage (29.2%) in the Pharma in the UK benchmark for July 2026, with 243 mentions and a net tone of +14.

July brought first place at 29.2%, alongside second-quarter results, the Dizal lung-cancer licence and Wainua’s failed late-stage trial. AstraZeneca reported higher second-quarter profit and revenue, driven by cancer and rare-disease medicine sales, and maintained its 2026 outlook. The company is also advancing an experimental obesity pill following a setback for Wainua. AstraZeneca reported H1 and Q2 2026 revenue and core EPS growth, reaffirming its full-year guidance and $80 billion 2030 revenue ambition. The release detailed pipeline milestones, approvals and new licensing agreements. AstraZeneca faces investor pressure after its Wainua phase III trial failure, which cut its market value and raised doubts about its $80bn 2030 sales target. The article assesses pipeline readouts, patent-expiry risks and the company's strategy under Pascal Soriot. AstraZeneca agreed to pay Dizal Pharmaceutical $600 million upfront for global rights to a lung-cancer drug.

Key messages:

- AstraZeneca reported higher second-quarter profit and revenue, driven by cancer and rare-disease medicine sales, and maintained its 2026 outlook. The company is also advancing an experimental obesity pill following a setback for Wainua.
- AstraZeneca reported H1 and Q2 2026 revenue and core EPS growth, reaffirming its full-year guidance and $80 billion 2030 revenue ambition. The release detailed pipeline milestones, approvals and new licensing agreements.
- AstraZeneca faces investor pressure after its Wainua phase III trial failure, which cut its market value and raised doubts about its $80bn 2030 sales target. The article assesses pipeline readouts, patent-expiry risks and the company's strategy under Pascal Soriot.
- AstraZeneca agreed to pay Dizal Pharmaceutical $600 million upfront for global rights to a lung-cancer drug.
- AstraZeneca said its partnered drug Wainua failed to meet the primary endpoint in a late-stage heart-disease trial. The trial did not reduce cardiovascular deaths and recurring heart problems as intended.

Leading themes:

- Financial Results & Pipeline: 49.0% of AstraZeneca's coverage (theme index 3.27, net tone +2)
- M&A & Licensing: 16.0% of AstraZeneca's coverage (theme index 1.04, net tone +92)
- Clinical Trials & Research: 15.2% of AstraZeneca's coverage (theme index 1.99, net tone −54)

Notable positive coverage:

- 27 July 2026, euronews.com: [AstraZeneca quarterly net profit rises 2% on strong cancer drug sales](https://www.euronews.com/business/2026/07/27/astrazeneca-quarterly-net-profit-rises-2-on-strong-cancer-drug-sales). AstraZeneca reported higher second-quarter profit and revenue, driven by cancer and rare-disease medicine sales, and maintained its 2026 outlook. The company is also advancing an experimental obesity pill following a setback for Wainua.
- 28 July 2026, biospace.com: [AstraZeneca results: H1 and Q2 2026](https://www.biospace.com/press-releases/astrazeneca-results-h1-and-q2-2026). AstraZeneca reported H1 and Q2 2026 revenue and core EPS growth, reaffirming its full-year guidance and $80 billion 2030 revenue ambition. The release detailed pipeline milestones, approvals and new licensing agreements.
- 30 July 2026, finance.yahoo.com: [AstraZeneca profit rises on strong cancer drug sales](https://finance.yahoo.com/healthcare/articles/astrazeneca-profit-rises-strong-cancer-112925184.html). AstraZeneca reported higher profit, supported by strong cancer-drug sales.

Notable negative coverage:

- 9 July 2026, reuters.com: [AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial](https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-ionis-drug-fails-meet-main-goal-late-stage-heart-disease-trial-2026-07-09/). AstraZeneca said its partnered drug Wainua failed to meet the primary endpoint in a late-stage heart-disease trial. The trial did not reduce cardiovascular deaths and recurring heart problems as intended.
- 9 July 2026, sharecast.com: [AstraZeneca shares slide on failure of cardiomyopathy trial](https://www.sharecast.com/news/news-and-announcements/astrazeneca-shares-slide-on-failure-of-cardiomyopathy-trial--22966834.html). AstraZeneca reported that its Phase III Wainua trial in ATTR-CM failed to meet its primary endpoint. Its shares fell following the announcement.
- 27 July 2026, reuters.com: [AstraZeneca's rare disease drug misses main goal in late-stage trial](https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-rare-disease-drug-misses-main-goal-late-stage-trial-2026-07-27/). AstraZeneca said Ultomiris failed its main endpoint in a late-stage trial for a post-stem-cell-transplant blood-vessel complication. The setback added to concerns about its pipeline.

- [AstraZeneca deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=astrazeneca&view=deep-dive)
- [AstraZeneca PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/astrazeneca.pdf)

### GSK

**Financial Results & Pipeline shaped GSK's media profile during July 2026**

GSK ranked 2nd of 10 by average monthly share of coverage (23.7%) in the Pharma in the UK benchmark for July 2026, with 197 mentions and a net tone of +30.

GSK remained prominent in July, when volume reached 197 and share was 23.7%, although it ranked second as tracked-company coverage expanded. July 2026: volume rose by 34 to 197 while share fell 3.4 points to 23.7% and rank moved to second; stories included the £1.9bn savings plan and £400m UK R&D investment. July 2026: GSK announced a £400m UK investment while preparing to move R&D activity from Stevenage to Cambridge, reported by the BBC. GSK will invest £400 million in Britain over three years, including a Cambridge R&D centre and upgrades at Ware, while leaving Stevenage by 2029. The investment is presented within the UK government's life-sciences strategy. GSK reported stronger-than-expected second-quarter revenue and profit, raised its margin outlook and launched a £1.9 billion cost-savings programme. It will reinvest savings in late-stage trials and relocate R&D from Stevenage to Cambridge with a £400 million UK investment.

Key messages:

- GSK will invest £400 million in Britain over three years, including a Cambridge R&D centre and upgrades at Ware, while leaving Stevenage by 2029. The investment is presented within the UK government's life-sciences strategy.
- GSK reported stronger-than-expected second-quarter revenue and profit, raised its margin outlook and launched a £1.9 billion cost-savings programme. It will reinvest savings in late-stage trials and relocate R&D from Stevenage to Cambridge with a £400 million UK investment.
- GSK launched a cost-saving programme and announced a new R&D centre in Cambridge, England, while increasing clinical-trial activity for priority pipeline medicines. The company aims to protect profitability as its HIV drug dolutegravir approaches patent expiry.
- GSK secured US approval for Jideytro in previously treated ROS1-positive NSCLC shortly after acquiring Nuvalent. The article presents the launch as validating GSK's oncology acquisition strategy and notes Pfizer's competing Lorbrena.
- GSK beat second-quarter earnings and revenue expectations, supported by growth in specialty medicines and vaccines. It announced a three-year cost-saving programme intended to fund R&D and business development while supporting margins.

Leading themes:

- Financial Results & Pipeline: 28.9% of GSK's coverage (theme index 1.22, net tone +12)
- UK Investment & Manufacturing: 27.9% of GSK's coverage (theme index 8.43, net tone +31)
- Leadership & Strategy: 12.7% of GSK's coverage (theme index 4.47, net tone +16)

Notable positive coverage:

- 29 July 2026, reuters.com: [GSK to invest £400 million in Britain over three years as it ramps up R&D efforts](https://www.reuters.com/legal/litigation/gsk-invest-400-million-britain-over-3-years-it-ramps-up-rd-efforts-2026-07-28/). GSK will invest £400 million in Britain over three years, including a Cambridge R&D centre and upgrades at Ware, while leaving Stevenage by 2029. The investment is presented within the UK government's life-sciences strategy.
- 28 July 2026, reuters.com: [GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs](https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-beats-second-quarter-profit-estimates-launches-252-billion-cost-savings-2026-07-28/). GSK reported stronger-than-expected second-quarter revenue and profit, raised its margin outlook and launched a £1.9 billion cost-savings programme. It will reinvest savings in late-stage trials and relocate R&D from Stevenage to Cambridge with a £400 million UK investment.
- 28 July 2026, qz.com: [GSK Q2 2026 earnings beat: £1.9B cost-savings plan launched](https://qz.com/gsk-cost-savings-program-drug-pipeline-q2-earnings-072826). GSK exceeded second-quarter profit expectations and launched a £1.9 billion annual cost-savings programme to fund late-stage R&D. It also confirmed a £400 million investment in a new Cambridge, England R&D centre.

Notable negative coverage:

- 17 July 2026, clinicaltrialsarena.com: [GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid](https://www.clinicaltrialsarena.com/news/gsk-drops-camlipixant-development-refractory-chronic-cough/). GSK has stopped developing camlipixant for refractory chronic cough after mixed Phase III results, reducing the expected value of its Bellus Health acquisition. It will continue a Phase IIb trial of the drug in irritable bowel syndrome.
- 17 July 2026, biopharmadive.com: [GSK shelves cough drug acquired in $2B deal](https://www.biopharmadive.com/news/gsk-camlipixant-cough-drug-shelved/825530/). GSK discontinued Phase 3 development of chronic-cough drug camlipixant after mixed results and failure to meet most trial goals. The setback removes a potential respiratory portfolio opportunity but analysts said it was not material to GSK's equity case.
- 17 July 2026, sharecast.com: [GSK shares fall as cough drug development axed](https://www.sharecast.com/news/news-and-announcements/gsk-shares-fall-as-cough-drug-development-axed--23055100.html). GSK ended development of camlipixant for refractory chronic cough after mixed Phase III results showed limited efficacy. Its shares declined following the decision.

- [GSK deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=gsk&view=deep-dive)
- [GSK PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/gsk.pdf)

### Novo Nordisk

**Novo Nordisk’s Wegovy expansion meets a broader pipeline test**

Novo Nordisk ranked 3rd of 10 by average monthly share of coverage (16.8%) in the Pharma in the UK benchmark for July 2026, with 140 mentions and a net tone of +13.

In July 2026, Novo Nordisk recorded 140 mentions, 16.8% of cohort coverage and rank #3, with net sentiment of +13. Coverage focused on Medicines Safety, Supply & Patient Use. July 2026: The Guardian reported that the Wegovy pill had gone on sale through UK high-street and online pharmacies. Novo Nordisk won European approval for oral Wegovy, following UK approval that has created substantial patient waitlists. The article contrasts Novo's first-mover position with Eli Lilly's competing oral obesity medicine. Wegovy semaglutide tablets have launched for sale in the UK, offering a daily oral alternative to weekly injections. The article outlines administration requirements, expected weight-loss results, and potential side effects. Private provider Get A Drip says it is among the first UK providers to offer newly MHRA-licensed oral Wegovy. The Novo Nordisk semaglutide tablet is available through private prescription for eligible patients.

Key messages:

- Novo Nordisk won European approval for oral Wegovy, following UK approval that has created substantial patient waitlists. The article contrasts Novo's first-mover position with Eli Lilly's competing oral obesity medicine.
- Wegovy semaglutide tablets have launched for sale in the UK, offering a daily oral alternative to weekly injections. The article outlines administration requirements, expected weight-loss results, and potential side effects.
- Private provider Get A Drip says it is among the first UK providers to offer newly MHRA-licensed oral Wegovy. The Novo Nordisk semaglutide tablet is available through private prescription for eligible patients.
- The Times reports strong UK private-market demand for Novo Nordisk's new daily Wegovy tablet, with major pharmacies recording high sales. The medicine is not expected to reach the NHS until next year and would initially be tightly rationed.
- Novo Nordisk lost more than $30 billion in market value after ziltivekimab failed a cardiovascular trial. The article notes the company has launched a Wegovy pill in the UK and describes its advertising dispute with Eli Lilly.

Leading themes:

- Medicines Safety, Supply & Patient Use: 52.1% of Novo Nordisk's coverage (theme index 4.45, net tone −10)
- Drug Approvals & Launches: 29.3% of Novo Nordisk's coverage (theme index 11.9, net tone +73)
- NHS Access & Pricing: 7.1% of Novo Nordisk's coverage (theme index 1.5, net tone −10)

Notable positive coverage:

- 16 July 2026, pharmaceutical-technology.com: [Novo secures European approval for oral Wegovy to extend lead over Lilly](https://www.pharmaceutical-technology.com/news/novo-secures-european-approval-for-oral-wegovy-to-extend-lead-over-lilly/). Novo Nordisk won European approval for oral Wegovy, following UK approval that has created substantial patient waitlists. The article contrasts Novo's first-mover position with Eli Lilly's competing oral obesity medicine.
- 7 July 2026, nottinghampost.com: [Wegovy weight loss pill on sale in UK this week - what you could lose](https://www.nottinghampost.com/news/health/wegovy-semaglutide-tablets-uk-cost-11047710). Wegovy semaglutide tablets have launched for sale in the UK, offering a daily oral alternative to weekly injections. The article outlines administration requirements, expected weight-loss results, and potential side effects.
- 24 July 2026, finance.yahoo.com: [Get A Drip among first providers of newly approved oral Wegovy in the UK](https://finance.yahoo.com/healthcare/articles/drip-among-first-providers-newly-133500469.html). Private provider Get A Drip says it is among the first UK providers to offer newly MHRA-licensed oral Wegovy. The Novo Nordisk semaglutide tablet is available through private prescription for eligible patients.

Notable negative coverage:

- 31 July 2026, forbes.com: [Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial](https://www.forbes.com/sites/tylerroush/2026/07/31/novo-nordisk-wipes-out-30-billion-in-market-value-after-failed-heart-drug-trial/). Novo Nordisk lost more than $30 billion in market value after ziltivekimab failed a cardiovascular trial. The article notes the company has launched a Wegovy pill in the UK and describes its advertising dispute with Eli Lilly.
- 1 July 2026, yahoo.com: [Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns](https://www.yahoo.com/news/science/articles/sublingual-semaglutide-offered-uk-practices-115724571.html). An unlicensed sublingual semaglutide product is being marketed to UK private doctors despite not having MHRA approval. Novo Nordisk warned that mass compounding poses significant patient-safety risks.
- 29 July 2026, telegraph.co.uk: ['Our spark has gone': The marriages ruined by Ozempic](https://www.telegraph.co.uk/news/2026/07/29/spark-gone-marriages-ruined-ozempic/). A UK feature examines reported relationship, libido and emotional changes associated with Ozempic and Wegovy use. It cites experts discussing potential behavioural effects of GLP-1 weight-loss medicines.

- [Novo Nordisk deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=novonordisk&view=deep-dive)
- [Novo Nordisk PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/novonordisk.pdf)

### Eli Lilly

**Lilly rebounded to second place as Foundayo launched in the UK**

Eli Lilly ranked 4th of 10 by average monthly share of coverage (11.7%) in the Pharma in the UK benchmark for July 2026, with 97 mentions and a net tone of +4.

A Newcastle woman describes losing more than 100lb after using Eli Lilly's Mounjaro through a digital pharmacy. The article discusses needle phobia, stigma and interest in oral weight-loss treatments in the UK. Eli Lilly has entered commercial negotiations with NHS England over donanemab after NICE previously rejected it on cost-effectiveness grounds. The talks may enable routine NHS access for eligible people with early Alzheimer's disease. Carolyn Harris MP describes losing 10 stone while using Mounjaro, alongside changes to diet and exercise. The article covers her experience of the medicine's effects on appetite and weight maintenance. A UK pilot will allow eligible patients in four areas to access Eli Lilly's Mounjaro without first seeing a GP. The programme concerns NHS access to the weight-loss medicine. A healthcare-news roundup reports that Eli Lilly and the UK Government are providing £85m for 12 obesity projects. The projects include digital support, advice services and AI-powered triage.

Key messages:

- A Newcastle woman describes losing more than 100lb after using Eli Lilly's Mounjaro through a digital pharmacy. The article discusses needle phobia, stigma and interest in oral weight-loss treatments in the UK.
- Eli Lilly has entered commercial negotiations with NHS England over donanemab after NICE previously rejected it on cost-effectiveness grounds. The talks may enable routine NHS access for eligible people with early Alzheimer's disease.
- Carolyn Harris MP describes losing 10 stone while using Mounjaro, alongside changes to diet and exercise. The article covers her experience of the medicine's effects on appetite and weight maintenance.
- A UK pilot will allow eligible patients in four areas to access Eli Lilly's Mounjaro without first seeing a GP. The programme concerns NHS access to the weight-loss medicine.
- A healthcare-news roundup reports that Eli Lilly and the UK Government are providing £85m for 12 obesity projects. The projects include digital support, advice services and AI-powered triage.

Leading themes:

- Medicines Safety, Supply & Patient Use: 66.0% of Eli Lilly's coverage (theme index 5.38, net tone −6)
- NHS Access & Pricing: 10.3% of Eli Lilly's coverage (theme index 2.29, net tone −20)
- Drug Approvals & Launches: 8.2% of Eli Lilly's coverage (theme index 1.21, net tone +13)

Notable positive coverage:

- 14 July 2026, walesonline.co.uk: [Woman overcame phobia and judgment to lose 100lbs in a year](https://www.walesonline.co.uk/news/health/woman-overcame-phobia-judgment-lose-34289104). A Newcastle woman described losing more than 100lb after using Eli Lilly's Mounjaro through a digital pharmacy. The article also discusses stigma around weight-loss injections and common gastrointestinal side effects.
- 30 July 2026, telegraph.co.uk: [Alzheimer's patients given boost as second drugmaker enters NHS talks](https://www.telegraph.co.uk/news/2026/07/30/alzheimers-patients-boost-second-drugmaker-nhs-talks/). Eli Lilly has entered commercial negotiations with NHS England over donanemab after NICE previously rejected it on cost-effectiveness grounds. The talks may enable routine NHS access for eligible people with early Alzheimer's disease.
- 7 July 2026, telegraph.co.uk: [Carolyn Harris MP: I lost 10st on Mounjaro after online trolls called me fat](https://www.telegraph.co.uk/health-fitness/diet/weight-loss/carolyn-harris-weight-loss/). Carolyn Harris MP describes losing 10 stone while using Mounjaro, alongside changes to diet and exercise. The article covers her experience of the medicine's effects on appetite and weight maintenance.

Notable negative coverage:

- 20 July 2026, wsj.com: [They Used GLP-1s to Lose Weight. They Ended Up in Treatment for Anorexia.](https://www.wsj.com/health/wellness/glp1-anorexia-wegovy-mounjaro-1bf4035c). A London nurse-in-training says using Eli Lilly's Mounjaro contributed to the development of anorexia. The article examines the risk that GLP-1 medicines may trigger disordered eating in susceptible users.
- 19 July 2026, independent.co.uk: [I tried 'nature's Mounjaro' to see if it worked. Here's what happened](https://www.independent.co.uk/health-and-wellbeing/mounjaro-tiktok-pink-weight-loss-hacks-b3016948.html). An article tests and rejects a viral pink-salt weight-loss fad, contrasting it with clinically tested GLP-1 medicines. It notes a substantial UK private-prescription price increase for Eli Lilly's Mounjaro.
- 19 July 2026, thesun.co.uk: [Nurse exposed flogging 'dangerous' illegal 'Godzilla' fat jabs to unsuspecting slimmers instead of Mounjaro](https://www.thesun.co.uk/health/39799445/nurse-sold-godzilla-fat-jabs-instead-mounjaro/). A UK nurse allegedly sold unlicensed retatrutide in unmarked vials while claiming it was Eli Lilly's Mounjaro, leaving some buyers injured or scarred. The MHRA and NHS England warn against counterfeit or unregulated weight-loss injections.

- [Eli Lilly deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=elililly&view=deep-dive)
- [Eli Lilly PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/elililly.pdf)

### Novartis

**Novartis visibility surged as oncology dealmaking dominated July coverage**

Novartis ranked 5th of 10 by average monthly share of coverage (5.8%) in the Pharma in the UK benchmark for July 2026, with 48 mentions and a net tone of +71.

July brought the strongest measured position, while coverage included the Myricx Bio acquisition, Entresto patent challenges and routine NHS use of Tafinlar for rare cancers. In July 2026, Novartis recorded 48 mentions, 5.8% of cohort coverage and rank #5. Novartis visibility surged as oncology dealmaking dominated July coverage. Novartis agreed to acquire UK-based Myricx Bio for up to $1.5bn, including milestone payments. The acquisition brings Myricx's pre-clinical oncology ADC platform into Novartis's oncology business. Generic-drug maker Stada has asked the UK High Court to invalidate patents covering Novartis' heart-failure medicine Entresto. The challenge could clear the way for a UK generic launch. NHS England will routinely use Novartis' Tafinlar for certain rare histiocytic cancers and a Pfizer-linked Adcetris combination for relapsed or refractory paediatric Hodgkin lymphoma. The decisions expand treatment access for around 200 patients annually.

Key messages:

- Novartis agreed to acquire UK-based Myricx Bio for up to $1.5bn, including milestone payments. The acquisition brings Myricx's pre-clinical oncology ADC platform into Novartis's oncology business.
- Generic-drug maker Stada has asked the UK High Court to invalidate patents covering Novartis' heart-failure medicine Entresto. The challenge could clear the way for a UK generic launch.
- NHS England will routinely use Novartis' Tafinlar for certain rare histiocytic cancers and a Pfizer-linked Adcetris combination for relapsed or refractory paediatric Hodgkin lymphoma. The decisions expand treatment access for around 200 patients annually.
- Novartis will acquire London-headquartered cancer biotech Myricx Bio for up to $1.5 billion. The deal expands Novartis's oncology pipeline and is another foreign takeover of a UK biotech.
- Novartis Faces Generic Challenge To Heart Drug Patent (law360.com, 1 July).

Leading themes:

- M&A & Licensing: 81.3% of Novartis's coverage (theme index 6.99, net tone +82)
- Patents & Intellectual Property: 10.4% of Novartis's coverage (theme index 20.39, net tone −20)
- NHS Access & Pricing: 6.3% of Novartis's coverage (theme index 1.22, net tone +100)

Notable positive coverage:

- 6 July 2026, manilatimes.net: [Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics](https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/brandon-capital-announces-agreement-for-novartis-to-acquire-portfolio-company-myricx-bio-to-advance-new-class-of-cancer-therapeutics/2378736). Novartis agreed to acquire UK-based Myricx Bio for up to $1.5bn, including milestone payments. The acquisition brings Myricx's pre-clinical oncology ADC platform into Novartis's oncology business.
- 6 July 2026, wsj.com: [Novartis to Buy Myricx Bio for Up to $1.5 Billion](https://www.wsj.com/health/pharma/novartis-to-buy-myricx-bio-for-up-to-1-5-billion-6e8ee865). Novartis agreed to acquire UK-based cancer biotech Myricx Bio for up to $1.5 billion to strengthen its oncology portfolio.
- 6 July 2026, pharmaceutical-technology.com: [Novartis to buy Myricx Bio in up to $1.5bn deal](https://www.pharmaceutical-technology.com/news/novartis-to-acquire-myricx-bio/). Novartis agreed to acquire UK-based cancer biotech Myricx Bio for up to $1.5bn. The deal adds Myricx's preclinical NMTi antibody-drug-conjugate payload platform to Novartis's oncology pipeline.

Notable negative coverage:

- 1 July 2026, law360.com: [Accord Challenges Novartis Blood Pressure Patent At Trial](https://www.law360.com/articles/2489531/accord-challenges-novartis-blood-pressure-patent-at-trial). Accord challenged Novartis' patent protections for a blood-pressure medicine in the London High Court. It argues the patent should be revoked.
- 1 July 2026, mlex.com: [Accord challenges Novartis blood pressure medicine patent in UK court](https://www.mlex.com/mlex/articles/2490151/accord-challenges-novartis-blood-pressure-medicine-patent-in-uk-court). Accord Healthcare is challenging Novartis' English patent for heart-failure medicine Entresto ahead of a proposed generic launch. The case concerns the validity of the patent.
- 1 July 2026, law360.com: [Novartis Faces Generic Challenge To Heart Drug Patent](https://www.law360.com/articles/2493682/novartis-faces-generic-challenge-to-heart-drug-patent). Generic-drug maker Stada has asked the UK High Court to invalidate patents covering Novartis' heart-failure medicine Entresto. The challenge could clear the way for a UK generic launch.

- [Novartis deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=novartis&view=deep-dive)
- [Novartis PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/novartis.pdf)

### Pfizer

**Pfizer’s visibility swung as safety coverage persisted**

Pfizer ranked 6th of 10 by average monthly share of coverage (4.3%) in the Pharma in the UK benchmark for July 2026, with 36 mentions and a net tone of +8.

In July 2026, Pfizer recorded 36 mentions, 4.3% of cohort coverage and rank #6, with net sentiment of +8. Coverage focused on Medicines Safety, Supply & Patient Use. The NHS is expanding eligibility for Pfizer's Abrysvo RSV vaccine to certain at-risk adults aged 65 to 74 from 1 September. The MHRA-approved vaccine is also available to older adults, eligible pregnant women and care-home residents. The Court of Appeal found that a process to remake £70 million excessive-pricing fines against Pfizer and Flynn Pharma was procedurally unfair. The ruling scrapped the redo ordered by the Competition Appeal Tribunal. The UK PMCPA publicly reprimanded Sanofi over misleading and disparaging claims concerning Pfizer's RSV vaccine. Sanofi may face further sanctions and has commissioned an external review of its UK compliance arrangements. UK women taking legal action against Pfizer allege a link between long-term Depo-Provera use and meningioma brain tumours. Pfizer says the contraceptive has an established efficacy and safety profile, while the MHRA says safety is continually reviewed.

Key messages:

- The NHS is expanding eligibility for Pfizer's Abrysvo RSV vaccine to certain at-risk adults aged 65 to 74 from 1 September. The MHRA-approved vaccine is also available to older adults, eligible pregnant women and care-home residents.
- The Court of Appeal found that a process to remake £70 million excessive-pricing fines against Pfizer and Flynn Pharma was procedurally unfair. The ruling scrapped the redo ordered by the Competition Appeal Tribunal.
- The UK PMCPA publicly reprimanded Sanofi over misleading and disparaging claims concerning Pfizer's RSV vaccine. Sanofi may face further sanctions and has commissioned an external review of its UK compliance arrangements.
- UK women taking legal action against Pfizer allege a link between long-term Depo-Provera use and meningioma brain tumours. Pfizer says the contraceptive has an established efficacy and safety profile, while the MHRA says safety is continually reviewed.
- Scottish women who developed meningiomas after using Pfizer's Depo-Provera call for stronger NHS risk warnings. The report covers legal claims, Scottish government action and potential MHRA consideration.

Leading themes:

- Medicines Safety, Supply & Patient Use: 27.8% of Pfizer's coverage (theme index 1.53, net tone −100)
- Vaccines & Public Health: 16.7% of Pfizer's coverage (theme index 13.25, net tone +100)
- M&A & Licensing: 16.7% of Pfizer's coverage (theme index 1.07, net tone +17)

Notable positive coverage:

- 1 July 2026, mirror.co.uk: [NHS vaccine on offer to millions from September 1 - eligibility](https://www.mirror.co.uk/news/health/nhs-vaccine-offer-millions-september-37373553). The NHS is widening access to Pfizer's Abrysvo RSV vaccine for certain clinically vulnerable adults aged 65 to 74 from 1 September. The MHRA-approved vaccine is intended to reduce severe RSV complications in vulnerable groups.
- 1 July 2026, law360.com: [Appeals Court Scraps Redo Of Pfizer, Flynn Drug Fines](https://www.law360.com/articles/2491760/appeals-court-scraps-redo-of-pfizer-flynn-drug-fines). The Court of Appeal found that a process to remake £70 million excessive-pricing fines against Pfizer and Flynn Pharma was procedurally unfair. The ruling scrapped the redo ordered by the Competition Appeal Tribunal.
- 2 July 2026, birminghammail.co.uk: [NHS confirms rule change for patients aged 65 to 74 from September 1](https://www.birminghammail.co.uk/news/midlands-news/nhs-confirms-rule-change-patients-34226320). NHS England is expanding RSV vaccination eligibility for clinically at-risk adults aged 65 to 74 from September 2026. The programme will continue to use Pfizer's Abrysvo vaccine.

Notable negative coverage:

- 1 July 2026, bbc.co.uk: ['I got three brain tumours after taking contraceptive injection'](https://www.bbc.co.uk/news/articles/c36y4g4y289o). A Scottish woman alleges that long-term use of Pfizer's Depo-Provera caused three meningioma tumours and is among women pursuing legal action. Pfizer says patient safety is its priority and that it continuously monitors its medicines.
- 12 July 2026, independent.co.uk: ['I have an inoperable brain tumour after having the contraceptive jab'](https://www.independent.co.uk/news/health/brain-tumour-contraceptive-injection-depo-provera-b3011322.html). UK women taking legal action against Pfizer allege a link between long-term Depo-Provera use and meningioma brain tumours. Pfizer says the contraceptive has an established efficacy and safety profile, while the MHRA says safety is continually reviewed.
- 2 July 2026, mirror.co.uk: [Nurse took contraceptive jab for years - now she has 'devastating' brain tumours](https://www.mirror.co.uk/news/uk-news/brain-tumour-contraceptive-injection-symptom-37378744). Women in Scotland are pursuing potential legal claims alleging that long-term use of Pfizer-manufactured Depo-Provera caused brain tumours. Pfizer and the MHRA say the medicine's safety is continually monitored.

- [Pfizer deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=pfizer&view=deep-dive)
- [Pfizer PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/pfizer.pdf)

### Roche

**Roche moved among access, research, diagnostics and dealmaking**

Roche ranked 7th of 10 by average monthly share of coverage (2.6%) in the Pharma in the UK benchmark for July 2026, with 22 mentions and a net tone of +73.

July brought licensing, Alzheimer’s research and NHS access together through the Astex agreement, a Scottish blood-test study, Columvi access and early trontinemab findings. July 2026: Roche’s trontinemab showed rapid amyloid reduction and fewer brain-imaging abnormalities in early studies — newscientist.com. Roche's Genentech agreed a global breast-cancer discovery and licensing deal with Cambridge-based Astex, worth up to $490 million in milestones plus royalties. Genentech will lead development and commercialisation of resulting therapies. Roche Diagnostics is sponsoring UK Hypo Awareness Week 2026 to promote hypoglycaemia awareness and safer diabetes care. The article also notes NHS reimbursement for its Accu-Chek SmartGuide glucose-monitoring system. Roche Diagnostics UK & Ireland is moving Accu-Chek SmartGuide users to its mySugr diabetes-management app. The integration combines glucose-monitoring data and predictive tools in one platform.

Key messages:

- Roche's Genentech agreed a global breast-cancer discovery and licensing deal with Cambridge-based Astex, worth up to $490 million in milestones plus royalties. Genentech will lead development and commercialisation of resulting therapies.
- Roche Diagnostics is sponsoring UK Hypo Awareness Week 2026 to promote hypoglycaemia awareness and safer diabetes care. The article also notes NHS reimbursement for its Accu-Chek SmartGuide glucose-monitoring system.
- Roche Diagnostics UK & Ireland is moving Accu-Chek SmartGuide users to its mySugr diabetes-management app. The integration combines glucose-monitoring data and predictive tools in one platform.
- A Scottish study involving more than 50 GP practices will assess Roche Diagnostics' Alzheimer's blood tests in up to 500 patients. The project aims to evaluate whether earlier primary-care diagnosis can improve access to care and treatment.
- Roche's trontinemab showed rapid amyloid reduction and fewer brain-imaging abnormalities in early Alzheimer's studies presented in London. Larger trials are planned to test effects on cognitive decline and prevention.

Leading themes:

- M&A & Licensing: 45.5% of Roche's coverage (theme index 3.06, net tone +60)
- Clinical Trials & Research: 18.2% of Roche's coverage (theme index 1.89, net tone +75)
- NHS Access & Pricing: 13.6% of Roche's coverage (theme index 2.76, net tone +100)

Notable positive coverage:

- 6 July 2026, pharmaphorum.com: [Roche looks to Astex in $515m breast cancer deal](https://pharmaphorum.com/news/roche-looks-astex-515m-breast-cancer-deal). Roche's Genentech unit formed a breast-cancer drug discovery alliance with UK-based Astex worth up to $515 million. Astex will provide candidates and discovery support for the programme.
- 6 July 2026, pharmaceutical-technology.com: [Roche pens $490m Astex breast cancer license deal](https://www.pharmaceutical-technology.com/news/roche-genentech-astex-breast-cancer-licensing-deal/). Roche's Genentech agreed a global breast-cancer discovery and licensing deal with Cambridge-based Astex, worth up to $490 million in milestones plus royalties. Genentech will lead development and commercialisation of resulting therapies.
- 6 July 2026, diabetestimes.co.uk: [Roche Diagnostics announced as sponsor of Hypo Awareness Week 2026](https://diabetestimes.co.uk/roche-diagnostics-announced-as-sponsor-of-hypo-awareness-week-2026/). Roche Diagnostics is sponsoring UK Hypo Awareness Week 2026 to promote hypoglycaemia awareness and safer diabetes care. The article also notes NHS reimbursement for its Accu-Chek SmartGuide glucose-monitoring system.

- [Roche deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=roche&view=deep-dive)
- [Roche PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/roche.pdf)

### MSD

**MSD coverage shifted from NHS access to clinical research**

MSD ranked 8th of 10 by average monthly share of coverage (2.4%) in the Pharma in the UK benchmark for July 2026, with 20 mentions and a net tone of −5.

July added the first participant in the Keytruda-combination NEOVACC lung-cancer vaccine trial and a favourable Dutch ruling in the Halozyme litigation. A Dutch court dismissed Halozyme's preliminary-injunction bid against MSD concerning Keytruda SC, amid wider European litigation. The article also reports related UK High Court proceedings and MSD's UK patent challenge. The article examines declining uptake of MSD's Gardasil 9 HPV vaccine in Northern Ireland despite evidence of its cancer-prevention benefits. It reports concerns about vaccine hesitancy and misinformation alongside calls to improve parental communication. Moderna beat second-quarter revenue estimates, supported partly by international COVID-19 vaccine sales and partnership payments including from the UK. The company also reported a norovirus trial setback while awaiting a US decision on its flu vaccine. GSK has ended camlipixant development for refractory chronic cough after mixed pivotal trial results, undermining a key asset acquired through Bellus Health. MSD's competing cough drug Lyfnua is discussed as having had limited commercial success.

Key messages:

- A UK patient is the first participant in the NEOVACC trial of a personalised lung-cancer vaccine at Clatterbridge Cancer Centre. The trial combines the vaccine with MSD's Keytruda immunotherapy.
- A Dutch court dismissed Halozyme's preliminary-injunction bid against MSD concerning Keytruda SC, amid wider European litigation. The article also reports related UK High Court proceedings and MSD's UK patent challenge.
- The article examines declining uptake of MSD's Gardasil 9 HPV vaccine in Northern Ireland despite evidence of its cancer-prevention benefits. It reports concerns about vaccine hesitancy and misinformation alongside calls to improve parental communication.
- Moderna beat second-quarter revenue estimates, supported partly by international COVID-19 vaccine sales and partnership payments including from the UK. The company also reported a norovirus trial setback while awaiting a US decision on its flu vaccine.
- GSK has ended camlipixant development for refractory chronic cough after mixed pivotal trial results, undermining a key asset acquired through Bellus Health. MSD's competing cough drug Lyfnua is discussed as having had limited commercial success.

Leading themes:

- Financial Results & Pipeline: 30.0% of MSD's coverage (theme index 1.21, net tone 0)
- Clinical Trials & Research: 25.0% of MSD's coverage (theme index 2.63, net tone −20)
- M&A & Licensing: 15.0% of MSD's coverage (theme index 0.96, net tone +67)

Notable positive coverage:

- 30 July 2026, pharmaphorum.com: [UK patient first in world to get novel lung cancer vaccine](https://pharmaphorum.com/news/uk-patient-first-world-get-novel-lung-cancer-vaccine). A UK patient is the first participant in the NEOVACC trial of a personalised lung-cancer vaccine at Clatterbridge Cancer Centre. The trial combines the vaccine with MSD's Keytruda immunotherapy.

- [MSD deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=msd&view=deep-dive)
- [MSD PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/msd.pdf)

### Moderna

**Moderna moved from tenth to fifth across an uneven period**

Moderna ranked 9th of 10 by average monthly share of coverage (2.0%) in the Pharma in the UK benchmark for July 2026, with 17 mentions and a net tone of +24.

July moved to ninth despite a small volume increase, alongside reporting on second-quarter revenue, UK contract deliveries and the norovirus trial setback. The MHRA authorised a UK phase I/II trial of Moderna's investigational mRNA cancer vaccine mRNA-4194 for Lynch syndrome. The study is being undertaken with the University of Oxford. Moderna has begun a phase 3 trial of its mRNA-1018 bird-flu vaccine in the UK and US, enrolling about 4,000 healthy adults. CEPI is funding the trial, and Moderna says it would reserve capacity for lower-income countries during a declared pandemic. Moderna beat second-quarter revenue estimates, supported partly by international COVID-19 vaccine sales and partnership payments including from the UK. The company also reported a norovirus trial setback while awaiting a US decision on its flu vaccine.

Key messages:

- The MHRA authorised a UK phase I/II trial of Moderna's investigational mRNA cancer vaccine mRNA-4194 for Lynch syndrome. The study is being undertaken with the University of Oxford.
- Moderna has begun a phase 3 trial of its mRNA-1018 bird-flu vaccine in the UK and US, enrolling about 4,000 healthy adults. CEPI is funding the trial, and Moderna says it would reserve capacity for lower-income countries during a declared pandemic.
- Moderna beat second-quarter revenue estimates, supported partly by international COVID-19 vaccine sales and partnership payments including from the UK. The company also reported a norovirus trial setback while awaiting a US decision on its flu vaccine.
- Moderna reported a narrower quarterly loss and higher revenue, supported by deliveries under a UK government contract. Its norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis.

Leading themes:

- Financial Results & Pipeline: 47.1% of Moderna's coverage (theme index 1.92, net tone 0)
- Clinical Trials & Research: 29.4% of Moderna's coverage (theme index 3.11, net tone +40)
- UK Investment & Manufacturing: 11.8% of Moderna's coverage (theme index 1.29, net tone +100)

Notable positive coverage:

- 1 July 2026, bioworld.com: [Moderna’s mRNA-4194 cleared for clinic for Lynch syndrome](https://www.bioworld.com/articles/731760-modernas-mrna-4194-cleared-for-clinic-for-lynch-syndrome). The MHRA authorised a UK phase I/II trial of Moderna's investigational mRNA cancer vaccine mRNA-4194 for Lynch syndrome. The study is being undertaken with the University of Oxford.
- 23 July 2026, medicaleconomics.com: [CDC won’t publish report showing COVID-19 vaccine effectiveness; former pharmacy president sentenced in $33M compounded drug kickback scheme; mRNA bird flu vaccine hits late-stage testing – Morning Medical Update](https://www.medicaleconomics.com/view/cdc-won-t-publish-report-showing-covid-19-vaccine-effectiveness-former-pharmacy-president-sentenced-in-33m-compounded-drug-kickback-scheme-mrna-bird-flu-vaccine-hits-late-stage-testing-morning-medical-update). Moderna has begun a phase 3 trial of its mRNA-1018 bird-flu vaccine in the UK and US, enrolling about 4,000 healthy adults. CEPI is funding the trial, and Moderna says it would reserve capacity for lower-income countries during a declared pandemic.

- [Moderna deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=moderna&view=deep-dive)
- [Moderna PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/moderna.pdf)

### Sanofi

**Access breakthroughs punctuated Sanofi’s volatile competitive position**

Sanofi ranked 10th of 10 by average monthly share of coverage (1.3%) in the Pharma in the UK benchmark for July 2026, with 11 mentions and a net tone of 0.

Regulatory scrutiny formed a separate strand, beginning with the PMCPA findings over claims comparing Beyfortus with Pfizer’s RSV vaccine and returning with a public reprimand in July. July 2026: share fell 2.0 percentage points to 1.3% and rank moved from sixth to tenth; contemporaneous developments included Sanofi’s plan to rebuild its Regeneron relationship and renewed regulatory reporting about Beyfortus claims. July 2026: Sanofi’s new chief executive set out plans to rebuild and potentially expand the Regeneron partnership, reported by BioPharma Dive. Dupilumab is being rolled out on the NHS for eligible COPD patients with raised eosinophil levels and recurrent flare-ups. NICE said the treatment can reduce flare-ups and improve lung function. GSK has partnered with UK biotech Engitix to identify liver-fibrosis regression targets, with potential payments and milestones linked to licensing. The article also reports Sanofi's EU approval for subcutaneous Sarclisa in multiple myeloma.

Key messages:

- Dupilumab is being rolled out on the NHS for eligible COPD patients with raised eosinophil levels and recurrent flare-ups. NICE said the treatment can reduce flare-ups and improve lung function.
- GSK has partnered with UK biotech Engitix to identify liver-fibrosis regression targets, with potential payments and milestones linked to licensing. The article also reports Sanofi's EU approval for subcutaneous Sarclisa in multiple myeloma.
- The UK PMCPA publicly reprimanded Sanofi over misleading and disparaging claims concerning Pfizer's RSV vaccine. Sanofi may face further sanctions and has commissioned an external review of its UK compliance arrangements.
- Sanofi faces a UK PMCPA public reprimand over Beyfortus promotional claims, alongside an FDA untitled letter concerning US marketing. The UK case followed concerns that claims could undermine confidence in RSV vaccination programmes.

Leading themes:

- M&A & Licensing: 27.3% of Sanofi's coverage (theme index 1.76, net tone +33)
- Financial Results & Pipeline: 18.2% of Sanofi's coverage (theme index 0.73, net tone 0)
- Medicines Safety, Supply & Patient Use: 18.2% of Sanofi's coverage (theme index 0.98, net tone −50)

Notable positive coverage:

- 1 July 2026, express.co.uk: ['Genuine hope' for COPD patients as new jab is rolled out on NHS](https://www.express.co.uk/life-style/health/2223459/copd-lung-disease-nhs-jab-injection). Dupilumab is being rolled out on the NHS for eligible COPD patients with raised eosinophil levels and recurrent flare-ups. NICE said the treatment can reduce flare-ups and improve lung function.
- 1 July 2026, firstwordpharma.com: [Biopharma bites: GSK's fibrosis deal, Sangamo's lifeline, and more from Sanofi, GNI](https://firstwordpharma.com/story/7539111). GSK has partnered with UK biotech Engitix to identify liver-fibrosis regression targets, with potential payments and milestones linked to licensing. The article also reports Sanofi's EU approval for subcutaneous Sarclisa in multiple myeloma.

Notable negative coverage:

- 22 July 2026, fiercepharma.com: [Sanofi reprimanded for disparaging Pfizer's RSV vaccine](https://www.fiercepharma.com/marketing/sanofi-reprimanded-disparaging-pfizers-rsv-vaccine). The UK PMCPA publicly reprimanded Sanofi over misleading and disparaging claims concerning Pfizer's RSV vaccine. Sanofi may face further sanctions and has commissioned an external review of its UK compliance arrangements.
- 22 July 2026, fiercepharma.com: [FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV](https://www.fiercepharma.com/marketing/fda-untitled-letter-calls-out-sanofi-emails-misleading-impression-beyfortus-indication). Sanofi faces a UK PMCPA public reprimand over Beyfortus promotional claims, alongside an FDA untitled letter concerning US marketing. The UK case followed concerns that claims could undermine confidence in RSV vaccination programmes.
- 17 July 2026, publichealthpolicyjournal.com: [A Baby Died, and Sanofi Quietly Ended RSV Vaccine Trial. The Company Says Death Was Unrelated to the Vaccine](https://publichealthpolicyjournal.com/a-baby-died-and-sanofi-quietly-ended-rsv-vaccine-trial-the-company-says-death-was-unrelated-to-the-vaccine/). The article reports that Sanofi ended an RSV vaccine trial after an infant death, while Sanofi says the death was unrelated to the vaccine and the programme ended for efficacy reasons. It also discusses claimed safety concerns involving historic or experimental RSV products from GSK, Pfizer and Moderna.

- [Sanofi deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07?entity=sanofi&view=deep-dive)
- [Sanofi PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07/reports/sanofi.pdf)

## Methodology

- **Share of coverage**: an organisation's mentions divided by all mentions of the organisations tracked in the same sector that month, in UK earned media. It is the central measure of media visibility in Omniscan benchmarks. "Average monthly share" is the mean of the monthly shares across the reporting period.
- **Mention**: one article that covers an organisation, classified as positive, neutral or negative in tone. Articles are deduplicated, and an organisation's own websites and passing sponsorship name-checks are excluded, so only earned media counts.
- **Net tone**: positive mentions minus negative mentions, as a percentage of all mentions (range −100 to +100).
- **Themes**: every article is assigned to one of the sector's editorial themes. A theme index above 1 means the organisation is covered on that theme more than its peers are; below 1 means less.
- **Calculation**: every figure is computed directly from the classified articles; narrative summaries are checked against those figures.
- **Sources**: UK national and international, trade and specialist, regional and local, and aggregator and syndication earned media.

## Other Pharma in the UK editions

- [UK pharma media reputation tracker – 2026 year to date](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd.md)
- [UK pharma media reputation tracker – H1 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1.md)
- [UK pharma media reputation tracker – August 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08.md)
- [UK pharma media reputation tracker – September 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-09.md)
- [UK pharma media reputation tracker – October 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10.md)
- [All Omniscan media benchmarks](https://www.omniscan.ai/benchmarks.md)

## How to cite

Omniscan, "UK pharma media reputation tracker", July 2026 (1 July 2026–31 July 2026), published 1 September 2026. https://www.omniscan.ai/benchmarks/uk-pharma-2026-07
